Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Topical Dermacyn
Dermacyn · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Topical Dermacyn |
| 2 | ACTIVE_COMPARATOR | Topical Dermacyn and levofloxacin |
| 3 | ACTIVE_COMPARATOR | Topical saline and levofloxacin |
| Name | Type | Description |
|---|---|---|
| Topical Dermacyn | DRUG | Topical Dermacyn once a day for 10 Days |
| Topical Dermacyn and Levofloxacin | DRUG | Topical Dermacyn once a day and levofloxacin 750 mg PO per day; both for 10 days |
| Topical Saline and Levofloxacin | DRUG | Topical saline once a day and levofloxacin 750 mg PO daily, both for 10 days |
Inclusion Criteria: * A patient must meet all of the following inclusion criteria to be enrolled in the study: 1. Males and females \> 18 years of age with diabetes mellitus (type 1 or type 2, controlled). 2. Presence of infected, non-ischemic diabetic foot ulcer that involves skin and deeper ...
Dermacyn is a topical wound care product being studied for the treatment of mild diabetic foot infections and diabetic foot ulcers. It is applied directly to the wound area. Sonoma Pharmaceuticals, Inc. is developing it as a small molecule therapy in the metabolic therapeutic area.
Dermacyn is developed by Sonoma Pharmaceuticals, Inc., which trades under the ticker SNOA. The company is the sponsor behind the clinical development program for this topical wound care product.
Dermacyn is in Phase 2 clinical development. It is an investigational product and has not been approved by the FDA. The Phase 2 program consists of one completed trial evaluating its use in diabetic foot infections.
Dermacyn has been evaluated in one Phase 2 trial, NCT00516958, titled a pilot study of the safety and clinical efficacy of Topical Dermacyn Wound Care to treat mild diabetic foot infections. The trial enrolled 65 participants in the United States and is completed.
Yes, Dermacyn is also known as Topical Dermacyn. The two names refer to the same wound care product developed by Sonoma Pharmaceuticals, Inc. for diabetic foot infections and foot ulcers.
The Phase 2 trial NCT00516958 was a randomized, active-controlled study that enrolled 65 participants aged 18 years and older of all sexes. It was not double-blind and did not use biomarker selection. The study evaluated topical Dermacyn wound care for mild diabetic foot infections.